REPORT OF THE THIRTY FIFTH SESSION OF THE JOINT COORDINATING BOARD (JCB)
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
DISTRIBUTION: RESTRICTED
TDR/JCB(35)/12.3
ORIGINAL: ENGLISH
REPORT OF THE THIRTY‐FIFTH SESSION OF
THE JOINT COORDINATING BOARD (JCB)
WHO Headquarters, Geneva, Switzerland
18‐20 June 2012
© World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases,
2012.
All rights reserved. This health information product is intended for a restricted audience only. It may not be
reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in
any form or by any means.TDR/JCB(35)/12.3
Page 2.
TABLE OF CONTENTS
Page
I Introduction ................................................................................................................................3
II Summary of proceedings............................................................................................................3
1. Statutory business ................................................................................................................................ 3
1.1 Election of the Chair and Vice Chair................................................................................................ 3
1.2 Approval of the Report of JCB(34) .................................................................................................. 4
1.3 Adoption of the Agenda ................................................................................................................. 4
2. Report by the Chair of the Joint Coordinating Board ........................................................................ 4
3. Report of the Standing Committee ...................................................................................................... 5
4. Report by the Chair of the Scientific and Technical Advisory Committee (STAC)........................... 6
5. Programme Review .............................................................................................................................. 6
5.1 Follow‐up to the JCB(34) decisions and recommendations ............................................................ 6
5.2 Interim External Review ................................................................................................................. 6
5.3 Operational and financial performance .......................................................................................... 6
6. Programme Budget 2012-2013 and future strategic direction ........................................................... 7
6.1 Future strategic direction and reorganization ................................................................................ 7
6.2 Workplan and Programme Budget for the biennium 2012‐2013 and outlook for the
biennium 2014‐2015 ...................................................................................................................... 8
7. Summary of recommendations and decisions of day 1 ...................................................................... 9
8. Review of TDR governance ................................................................................................................. 9
9. Resource Mobilization and Communications Strategy .................................................................... 10
10. Technical presentation ...................................................................................................................... 11
11. Global Report for Infectious Diseases of Poverty............................................................................. 11
12. Selection of JCB members ................................................................................................................ 12
12.1 Results of the election of four members under Paragraph 2.2.1 of the TDR
Memorandum of Understanding .................................................................................................. 12
12.2 Selection of two members of the JCB according to Paragraph 2.2.3 of the TDR
Memorandum of Understanding .................................................................................................. 12
13. Membership of the Scientific and Technical Advisory Committee (STAC) .................................... 12
14. Review of TDR key achievements since JCB(34) and outlook 2012-2013 ...................................... 13
15. Summary of decisions and recommendations .................................................................................. 13
16. Closing session................................................................................................................................... 13Report of the 35th Session of the JCB
Page 3.
I Introduction
The Thirty‐fifth Session of the Joint Coordinating Board (JCB) of the UNICEF/UNDP/World Bank/WHO
Special Programme for Research and Training in Tropical Diseases (TDR) took place at WHO
headquarters in Geneva from 18 to 20 June 2012. The session was chaired by Dr Sue Kinn from the
United Kingdom and attended by all JCB members except Brazil, Côte d’Ivoire, Portugal and the
United Arab Emirates who sent their apologies. Representatives of several governments and
organizations also attended the session as observers (see Annex 2).
The deliberations of JCB(35) focused on TDR’s new strategy 2012‐2017, TDR’s achievements since
JCB(34) and the Programme Budget and work plan for the Biennium 2012‐2013. Important decisions
taken included the adoption of TDR’s new strategy and measures to further strengthen TDR
governance.
II Summary of proceedings
Opening session
Key messages
In her opening remarks, Dr Sue Kinn, welcomed the JCB members and observers. She extended a
warm welcome to Dr John Reeder, the new Director of TDR. She also extended a special welcome to
the Drugs for Neglected Diseases initiative (DNDi) which joined the JCB in January 2012 as the first
nongovernmental member since the Rockefeller Foundation’s membership on the JCB ended in
1981, and to Dr Mario Henry Rodriguez‐Lopez, Chair of the TDR Scientific and Technical Advisory
Committee (STAC), who played an important role in TDR’s strategic re‐orientation.
Dr Hiroki Nakatani, WHO Assistant Director‐General for HIV/AIDS, TB, Malaria and Neglected
Tropical Diseases, welcomed the delegates on behalf of WHO and conveyed special greetings from
Dr Margaret Chan, Director‐General of WHO. Dr Nakatani paid tribute to TDR’s rich history of
achievements, which includes development of tools and strategies that lie at the heart of efforts to
eliminate diseases such as leprosy, Chagas' disease, lymphatic filariasis and onchocerciasis (African
river blindness) and the provision of evidence for policies and approaches now used to control a
number of infectious diseases, including malaria, dengue and visceral leishmaniasis. He underlined
the importance of this Board meeting, which comes at a time when TDR looks forward to guidance
and support from the JCB in moving forward.
Dr John Reeder, Director TDR, conveyed his commitment and motivation to lead TDR through a
challenging period, expressing confidence that TDR is emerging reinvigorated, and thanking the JCB
for its continued support and guidance.
1. Statutory business
1.1 Election of the Chair and Vice Chair
The Chair JCB expressed her appreciation and thanks for the support she received from the Vice‐
Chair JCB, Dr Modest Mulenga from Zambia. Dr Kinn also extended her thanks to the outgoing
Rapporteur, Dr Maria‐Teresa Bejarano from Sweden, for her support and excellent work.TDR/JCB(35)/12.3
Page 4.
Decisions
Dr Modest Mulenga from Zambia was elected as Vice‐Chair JCB for a second term of one
year.
Dr Ignace Ronse from Belgium was elected as Rapporteur for JCB(35).
1.2 Approval of the Report of JCB(34)
The Report of JCB(34) was circulated to the members of the JCB in July 2011.
Decisions
The JCB(34) report was approved.
Future JCB reports will be sent to JCB representatives for electronic approval within two
weeks of the meeting. There will be no need to table the report again for approval at the
next JCB.
1.3 Adoption of the Agenda
The Draft Agenda of JCB(35) was circulated to the JCB members and observers in March 2012 and
the Draft Annotated Agenda was made available on the JCB SharePoint site a month before the
meeting.
Decision
The Agenda for JCB(35) was approved.
2. Report by the Chair of the Joint Coordinating Board
Key messages
The Chair JCB briefly recalled some of the main recommendations made by JCB(34) and
commended TDR for the follow‐up action taken.
A key highlight happened the day after JCB(34) closed when TDR was awarded the 2011 Gates
Award for Global Health at a ceremony in Washington DC. This is a great achievement and
recognition of TDR's work over its 35 year history.
In July 2011, Chair JCB wrote a letter to the TDR co‐sponsors and launched an appeal with TDR’s
donors for additional funding. Three key donors of TDR – Japan, Sweden and the United Kingdom ‐‐
provided TDR with special additional financial resources.
At the end of August 2011, Dr Robert Ridley left TDR to become the Pro Vice Chancellor of the
University of Malawi. Dr Marie‐Paule Kieny, WHO Assistant Director‐General for Innovation,
Information, Evidence and Research and TDR Special Programme Coordinator, took up the position
of ad‐interim Director of TDR until the new Director, Dr John Reeder, took office in February 2012.Report of the 35th Session of the JCB
Page 5.
In November 2011, the Chair and Vice‐Chair JCB attended, ex officio, the meeting of the Standing
Committee in Berlin. They also participated in the deliberations of the Standing Committee in
Washington DC in February 2012. The Chair and Vice Chair also actively participated in a number of
Standing Committee consultations by teleconference.
In December 2011, the JCB received and approved electronically, a revised Programme Budget for
the Biennium 2012‐2013. This marked an important milestone in TDR’s reorganization process.
Decision
The report of the Chair JCB was accepted.
3. Report of the Standing Committee
Key messages
The TDR Standing Committee (SC) recommended that TDR should refocus its activities in two areas
where the Programme has comparative advantages and is recognized to be a key global player:
(i) implementation research in close partnership with disease control programmes; and (ii) capacity
building in disease endemic countries for health research on infectious diseases of poverty.
The SC welcomed the presentation made in Washington by the new Director TDR shortly after
taking office and endorsed the strategic directions that he outlined. The SC recommended
including the following as key guiding principles during the strategy development process: value for
money, quality, equity and innovation.
The SC discussed extensively the issue of TDR governance and recommended that action should be
taken to enhance accountability and to clarify the role and function of the TDR governing bodies
and, in particular, decision‐making processes.
The SC recommended that all TDR project proposals should be submitted on the basis of full cost
recovery (TDR recently introduced this policy).
The SC recommended a TDR Programme Budget for the Biennium 2012‐2013 of US$ 60 million and
a further reduction of staff to 30 from its current staff of 58.
Decision
The report of the Standing Committee was accepted.TDR/JCB(35)/12.3
Page 6.
4. Report by the Chair of the Scientific and Technical Advisory Committee
(STAC)
Key messages
The Chair of STAC, Professor Mario Henry Rodriguez‐Lopez, highlighted the role STAC played in the
review of TDR’s portfolio of activities, the Programme Budget 2012‐2013 and the strategy setting
process. As Chair of STAC, he participated in the deliberations of the Standing Committee and
chaired a meeting of a sub‐group of the STAC that took place in November 2011, as well as the 2012
annual meeting of STAC which took place in April 2012.
STAC provided useful guidance in the elaboration of TDR’s new strategy and gave its endorsement
to the strategic orientations. STAC also advised on the results‐based approach to priority setting
and budget allocation.
Feedback was provided on how to best utilize TDR’s existing networks and on linking with WHO
disease control programmes to strengthen collaboration in addressing priorities.
Decision
The report of the STAC was accepted.
Note: A comprehensive STAC report was made available to the JCB.
5. Programme Review
5.1 Follow‐up to the JCB(34) decisions and recommendations
Key messages
TDR has kept up‐to‐date a detailed table with actions taken in response to the decisions and
recommendations from JCB(34). Examples from the table were presented.
A TDR risk management framework is under development, addressing risks associated with
financial, portfolio and project management.
5.2 Interim External Review
Key message
The scope and quality of the analysis provided by the Interim External Review was welcomed by the
JCB. The Review has been particularly useful for the future strategic orientations of TDR and for the
review of TDR’s governance. Actions have been taken to address the key recommendations.
5.3 Operational and financial performance
Key messages
TDR has now put into place the recommendation to stop subsidizing designated funding (DF)
projects using core funding (UD) and is currently renegotiating donor agreements to include full
staff costs wherever possible.Report of the 35th Session of the JCB
Page 7.
TDR presented the Results Report for the second year. The presentation was appreciated by the JCB
and is regarded as a useful reporting tool.
Designated funding is deposited and managed in separate accounts.
TDR should differentiate clearly between designated and undesignated (core) funding for budget
planning and reporting
Designated funding should be listed by project.
Decision
The TDR 2011 Results Report was endorsed.
Recommendation
The Performance Assessment Framework needs to be updated, adjusting expected results
and targets to the outcomes of the new strategy and workplan, ensuring measures for
outcomes of publications, training courses and networks are included.
6. Programme Budget 2012‐2013 and future strategic direction
6.1 Future strategic direction and reorganization
Key messages
The presentation of the new strategy by Director TDR generated a lot of positive feedback. The JCB
commended the focus on health impact and the cross‐sectoral approach.
The JCB welcomed the proposed new working model, which focuses more on facilitation and
coordination than direct implementation by TDR staff. The JCB encouraged TDR to further step up
its collaboration with countries, partners (including co‐sponsors) and networks.
There was a consensus that the JCB should not micro‐manage TDR’s re‐profiling process, which will
follow WHO’s rules and regulations and should leave TDR with the required skillset to implement its
new strategy. However, the JCB reaffirmed that the reorganization should be carried out within the
approved budget framework (which foresees a TDR staff ceiling of 30 people).
Decision
JCB approved TDR’s new strategy which focuses on intervention and implementation
research, research capacity strengthening and knowledge management.
Recommendation
JCB advised that ethics networks, research management strengthening and advocacy for
global and regional policies should be covered under research capacity strengthening and
networks.TDR/JCB(35)/12.3
Page 8.
6.2 Workplan and Programme Budget for the biennium 2012‐2013 and outlook
for the biennium 2014‐2015
Key messages
At its meeting in October 2011, the Standing Committee reviewed various budget scenarios and
recommended a budget ceiling of US$ 60 million based on a staff count of 30. In December 2011
this budget was approved, following electronic consultation by the JCB.
The JCB responded positively to the fact that for the first time the TDR budget is based entirely on
expected results and each expected result is costed.
The JCB recognized the fact that STAC has looked not only at the technical aspects but has also
provided guidance in allocating budgets for expected results.
Decisions
JCB authorizes TDR to accept designated funding beyond the current budget ceiling for
2012‐2013, providing that the following three criteria are met. The designated funding:
1. supports the achievement of outcomes included in the TDR strategy.
2. fully covers the cost of activities and staff, thereby requiring no cross‐subsidy from core
resources (undesignated funds).
3. is monitored in separate accounts.
Any designated funding beyond the approved ceiling which does not meet the above
criteria, for example because it requires co‐investment of core resources, shall only be
accepted by TDR following consideration of the Standing Committee and a decision by the
JCB.
JCB reconfirmed its approval of the 2012‐2013 biennium Programme Budget of
US$ 60 million, originally approved in December 2011.
Recommendations
A conservative approach should continue to be used when forecasting income.
In the future TDR should develop budget scenarios in order to be able to adjust the budget,
if necessary, to the actual income received. Future Programme Budgets should contain a
clear differentiation for each budget line between designated and undesignated funding.
TDR co‐sponsors are encouraged to financially support joint activities with TDR
(e.g. TDR/UNICEF implementation research).
TDR should give priority to supporting research activities that are part of disease endemic
countries’ comprehensive national health plans.
The budget line for coordination should be deleted and integrated into the budget lines for
output.Report of the 35th Session of the JCB
Page 9.
7. Summary of recommendations and decisions of day 1
The decisions and recommendations of day 1 were summarized and discussed at the beginning of day 2.
8. Review of TDR governance
Key discussion points
Following JCB(34) and the recommendations of the Interim External Review, a JCB Working Group
on Governance was created to consider options for increasing the effectiveness of TDR governance.
Options were presented for
a. decreasing the membership of the JCB under paragraph 2.2.2 of the MOU;
b. prolonging the term of office of the Chair and Vice Chair JCB; and
c. creating a JCB sub group with delegated power of authority from the JCB to take decisions on
matters requiring attention in between the annual sessions of the JCB, and to facilitate
decision‐making by the JCB.
Two options were also presented for reforming the Standing Committee:
a. to discontinue the ex officio participation in the Standing Committee and focus its
deliberations in particular on matters related to the co‐sponsorship of the Programme; and
b. to continue the current practice but enlarge the participation in the Standing Committee and
make it more representative.
The JCB supported a reduction of membership of the JCB under paragraph 2.2.2 of the MOU, but
pointed out that this should not affect the important role that developing countries play in the
governance of TDR, but rather constitute a stimulus to form informal constituencies or apply for JCB
membership as resource contributors.
There was broad agreement around the expectation that JCB members should more closely engage
in the governance process by nominating representatives who could stay in contact with the
secretariat throughout their term of membership, including in between the annual JCB sessions.
The proposal to extend the term of office of the Chair JCB from 2 to 3 years and for the Vice‐Chair
JCB from 1 to 2 years was welcomed for ensuring continuity and strengthening the effectiveness of
their important function and role.
Following a rich discussion, the JCB opted for strengthening the current practice in respect of the
Standing Committee meetings, including by providing the Standing Committee with Standard
Operating Procedures (SOPs).
The JCB decided not to create a JCB sub‐group, but agreed with the possibility to establish, on a
temporary basis, task related ad hoc committees if and when required, to deliberate on particular
issues and/or prepare for JCB decision‐making.TDR/JCB(35)/12.3
Page 10.
Decisions
JCB decided to reduce its membership under paragraph 2.2.2 of the Memorandum of
Understanding (MoU) from twelve to six members (one per WHO region). Informal
constituencies could be formed under paragraph 2.2.2 to allow further countries to be
represented on the JCB, but funding support to participate in the JCB will be limited to one
representative per region.
The term of office of the Chair of the JCB is extended from 2 to 3 years and the Vice‐Chair
from 1 to 2 years.
The Standing Committee will systematically expand its deliberations beyond the four
co‐sponsors of TDR to include ex‐officio participation of the Chair and the Vice‐Chair of the
JCB, one representative of the JCB resource contributors group, one representative of the
DEC group and the chair of STAC. The representatives of the resource contributors group and
DECs will be nominated by the JCB.
The Standing Committee will develop its own standard operating procedures (SOPs), for
review by WHO Legal Counsel and submission to the JCB for its approval. The SOPs should
include the expanded ex officio participation in the Standing Committee’s deliberations.
The representative of Belgium was nominated as the representative of the JCB resource
contributor group and the representative of Djibouti was nominated as the representative
from the JCB DEC group in the expanded Standing Committee deliberations.
Recommendation
JCB recommended that members give clear terms of reference to their representatives in
order to allow them to perform effectively on the JCB.
9. Resource Mobilization and Communications Strategy
Key messages
The fundraising environment remains challenging, however there are potential new opportunities
for TDR to mobilize resources with an increased focus on achieving the Millennium Development
Goals, the focus on climate and environmental change, strengthening health systems and evidence‐
based delivery of health programmes.
Programme efficiency and effectiveness are important for donor funding decisions. Donors pay
more attention today to transaction costs, impact assessments, evaluations and reporting on results
achieved. The TDR Performance Assessment Framework is a key tool in this regard and should
demonstrate the value and comparative advantage of undesignated funding.
The JCB commended the continued strong commitment of key donors and encouraged all JCB
members to find ways of supporting TDR in their countries and regions. Director TDR intends to
promote TDR’s new strategy with existing and potential new donors.
Disease endemic countries are encouraged to duly acknowledge the research support provided by
TDR and to recognize the importance of their partnership with TDR.
TDR’s recognized convening power and reputation for high quality research should be promoted as
key comparative advantages of the Programme.Report of the 35th Session of the JCB
Page 11.
Recommendations
TDR core contributors should harmonize their reporting requirements and accept TDR’s
reporting through the JCB.
Director TDR should engage in a high level dialogue with the Global Fund to Fight AIDS,
Tuberculosis and Malaria to explore collaboration aimed at promoting evidence‐based
sustainable interventions.
TDR should further strengthen its collaboration with WHO’s disease control programmes.
10. Technical presentation
Dr Sodiomon Sirima, Director of the National Malaria Research and Training Center in Burkina Faso gave
a presentation on TDR‐led implementation research for better control of pneumonia and malaria at
community level in Burkina Faso.
Key message
JCB members noted the collaborative approach between the centre, TDR and other stakeholders
and emphasized the need to link such research projects to national health programmes in countries
to foster long term sustainability.
11. Global Report for Infectious Diseases of Poverty
Professor David Molyneux from the Liverpool School of Tropical Medicine highlighted key issues from
the Global Report, underlining the substantive body of knowledge reflected in the report which should
find its way to practical application.
Key message
The JCB commended the scope of the report and TDR for its role in facilitating its publication,
bringing together different sets of expertise. The report merits wide dissemination.TDR/JCB(35)/12.3
Page 12.
12. Selection of JCB members
12.1 Results of the election of four members under Paragraph 2.2.1 of the TDR
Memorandum of Understanding
Elections
JCB re‐elected for membership from 1 January 2013 until 31 December 2016 the constituencies
of:
(1) Germany and Luxembourg
(2) Panama and Spain
(3) United Kingdom of Great Britain and Northern Ireland and the United States
JCB elected as a new member from 1 January 2013 until 31 December 2016:
(4) Turkey
12.2 Selection of two members of the JCB according to Paragraph 2.2.3 of the TDR
Memorandum of Understanding
Elections
JCB re‐elected for membership from 1 January 2013 until 31 December 2016:
(1) Zambia
JCB elected as a new member from 1 January 2013 until 31 December 2016:
(2) Burkina Faso
13. Membership of the Scientific and Technical Advisory Committee (STAC)
Key discussion points
JCB discussed the options proposed by the JCB Working Group on Governance, considering also the
input received from Chair STAC. A smaller STAC was considered to enhance its effectiveness and to
be in line with the reduction of TDR staff.
JCB recognized, however, that STAC may require co‐opting external experts and recommended this
to be done within the approved budget.
Decision
JCB decided to reduce the STAC membership from 21 to 15 members with the possibility for
the Chair to co‐opt experts on an ad hoc basis when and if needed and within the budget
allocated to STAC.Report of the 35th Session of the JCB
Page 13.
14. Review of TDR key achievements since JCB(34) and outlook 2012‐2013
Key messages
JCB commended the Director TDR for his presentation which was considered useful for the donors
and for fundraising.
Recommendation
JCB advised TDR to give more visibility to donors of undesignated (core) funds when
reporting on its achievements.
15. Summary of decisions and recommendations
Key messages
The Rapporteur presented the decisions and key recommendations of JCB(35) which were noted
with thanks by the Board.
16. Closing session
Concluding remarks
Dr Marie‐Paule Kieny, ADG/IER, expressed her appreciation and thanks for the continued
commitment demonstrated at this meeting by the JCB participants towards the Special Programme.
The Chair of JCB thanked the participants and TDR staff who all contributed to the success of this
annual session of the Board.
Decision
JCB(36) will take place in Geneva from 17‐19 June 2013.
Recommendation
Consideration should be given to reducing the duration of the JCB meeting to 2 full days.TDR/JCB(35)/12.3
Page 14.
ANNEX 1
AGENDA OF THE THIRTY-FIFTH SESSION OF THE
JOINT COORDINATING BOARD (JCB)
MONDAY, 18 JUNE
Time Agenda item Action Reference Documents
09:00-09:30 Opening Remarks
Dr Sue Kinn, Chair of JCB
Dr Hiroki Nakatani, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases
Dr John Reeder, Director TDR
09:30-10:00 1. Statutory business
1.1 Election of the Vice-Chair and Rapporteur Decision on proposed
extension of term of office
TDR will propose an amendment to the MOU to extend
the term of office of the Chair and Vice-Chair, JCB. of Chair and Vice-Chair
JCB
Election of Vice Chair and
Rapporteur from among the
JCB members
1.2 Approval of the Report of JCB(34) Approval of JCB(34) report Report JCB(34)
TDR/JCB(34)/11.3
It is proposed that future JCB reports will only summarize Decision on proposed new
recommendations and decisions and will be circulated for format of JCB reports and
electronic approval within two weeks of the meeting. approval procedure
1.3 Adoption of the Agenda Adoption of agenda Draft Agenda
TDR/JCB(35)/12.1
Draft Annotated Agenda
TDR/JCB(35)12.1a
10:00-10:10 2. Report by the Chair of the Joint Information
Coordinating Board
Dr Sue Kinn, Chair since JCB(34), will report on her
activities as Chair since the Thirty-fourth JCB Session.
10:10-10:20 3. Report of the Standing Committee Information
Dr Armin Fidler, Representative of the World Bank and
current Chair of the Standing Committee, will report on
the Standing Committee’s activities since JCB(34).
10:20-10:50 COFFEE BREAK
10:50-11:30 4. Report by the Chair, TDR Scientific and Information and approval of Report Chair STAC
Technical Advisory Committee (STAC) STAC report TDR/STAC(34)/12.3
Professor Mario Henry Rodriguez-Lopez, Chair of STAC,
will provide a summary of the activities of STAC and
present the STAC report.Report of the 35th Session of the JCB
Page 15.
MONDAY, 18 JUNE (continued)
Time Agenda item Action Reference Documents
11:30-13:00 5. TDR programme review
11:30-11:40 5.1 Follow-up to the JCB(34) decisions and Information Report JCB(34)
recommendations (pages 3-7)
TDR/JCB(34)/11.3
Dr John Reeder, Director TDR, will provide an overview
on the follow-up action taken on decisions and
recommendations of JCB(34).
11:40-11:55 5.2 Interim External Review Information Interim External Review and
Evaluation
Dr Sue Kinn, Chair JCB, will present the key findings of (December 2011)
the External Review and the follow-up action taken by
TDR. Interim External Review –
Briefing notes for the JCB
TDR/JCB(35)/12.14
11:55-13:00 5.3 Operational and financial performance Information and TDR Financial Report
endorsement of TDR 2010-2011 and Financial
Dr Beatrice Halpaap, Programme and Portfolio Manager, Situation as at 1 May 2012
will present an overview of TDR’s financial performance Results Report 2011
TDR/JCB(35)/12.4/rev1
in the biennium 2010-2011 and outline the current
Opinion of the External
financial situation of TDR.
Auditor of WHO and Audited
Dr Fabio Zicker, TDR Coordinator, will provide an TDR financial statements for
overview on TDR’s operational performance. the 2010-2011 biennium
TDR/JCB(35)/12.5
TDR Results Report 2011
TDR/JCB(35)/12.6
TDR Biennial Report
2010-2011
ISBN 978 92 4 150356 3
13:00-14:30 LUNCH BREAK
14:30-18:00 6. Programme Budget 2012-2013 and future
strategic directions
14:30-15:30 6.1 Future strategic direction and reorganization Endorsement of proposed Draft TDR Strategic Plan
strategic directions and 2012-2017
Dr John Reeder will present the proposed future strategic TDR/STRA/12.2
direction of TDR and its planned further reorganization. reorganization
15:30-16:00 COFFEE BREAK
16:00-17:00 6.1 Future strategic direction and reorganization
(continued)
17:00-18:00 6.2 Workplan and Programme Budget for the Endorsement of Workplan TDR Programme Budget for
biennium 2012-2013 and outlook for the and Programme Budget for the Biennium 2012-2013
biennium 2014-2015 the Biennium 2012-2013 TDR/JCB(35)/12.8
Dr Beatrice Halpaap will present the key elements of the
Workplan and Programme Budget for the biennium
2012-2013 and provide a financial outlook for the
biennium 2014-2015.
18:00-20:00 JCB RECEPTION (WHO CAFETERIA, MAIN BUILDING)TDR/JCB(35)/12.3
Page 16.
TUESDAY, 19 JUNE
Time Agenda item Action Reference Documents
09:00-09:30 7. Summary of recommendations and Information and discussion
decisions of day 1
The Rapporteur will present a summary of
recommendations and decisions.
09:30-11:00 8. Review of TDR governance Decisions on strengthening Strengthening TDR
TDR governance Governance: Options for
A representative of the JCB Working Group on decision-making by JCB(35)
Governance, will present the proposals of the JCB TDR/JCB(35)/12.9
Working Group on TDR governance.
Memorandum of
Understanding
TDR/CP/78.5/Rev.2008
11:00-11:30 COFFEE BREAK
11:30-12:30 9. Resource Mobilization and Advice and recommendations Update on Resource
Communications Strategy on TDR’s resource Mobilization and Revenue
mobilization and Forecast
Mr Meinrad Studer, Manager, External Relations and communications priorities TDR/JCB(35)/12.10
Governing Bodies, will point out priorities and challenges
TDR Communications and
for resource mobilization. Advocacy Plan for 2012
Ms Jamie Guth, Communications Manager, will outline and beyond
TDR’s communications strategy and priorities. TDR/JCB(35)/12.11
12:30-14:00 LUNCH BREAK
14:00-15:00 10. Technical Presentation Information
TDR-led implementation research for better control
of pneumonia and malaria at community level in
Burkina Faso
Dr Sodiomon Sirima, Director, National Malaria Research
and Training Center, Burkina Faso, will present the
ongoing TDR community-based implementation research
in Burkina Faso. His presentation will be preceded by the
screening of a short film on the project.
15:00-15:30 COFFEE BREAK
15:30-16:30 11. Global Report for Infectious Diseases of Discussion and Global Report for
Poverty recommendations on the Research on Infectious
dissemination of and follow- Diseases of Poverty
Professor David Molyneux, Liverpool School of Tropical up to the Global Report ISBN 978 92 4 156 448 9
Medicine and co-author of the Global Report for
Research on Infectious Diseases of Poverty, will offer
some reflections on key messages and follow-up actions.
16:30-17:00 Summary of recommendations and decisions of Information and discussion
day 2
The Rapporteur will present a summary of the
recommendations and decisions.Report of the 35th Session of the JCB
Page 17.
WEDNESDAY, 20 JUNE
Time Agenda item Action Reference Documents
08:30-09:00 Closed meeting of TDR resource contributors for the Selection of four JCB
selection of four JCB members under paragraph members under paragraph
2.2.1 of the TDR Memorandum of Understanding 2.2.1 of the MOU
09:00-09:45 12. Selection of JCB members Note on the membership
of the JCB
TDR/JCB(35)/12.12
History of JCB
Membership, 1978-2012
12.1 Results of the election of four members under Information
Paragraph 2.2.1 of the TDR Memorandum of
Understanding
12.2 Selection of two members of the JCB Selection of two JCB
according to Paragraph 2.2.3 of the TDR members under paragraph
Memorandum of Understanding 2.2.3 of the MOU
09:45:10:15 13. Membership of the Scientific and Technical Decision on size of STAC Membership
membership and call for including Terms of
Advisory Committee (STAC) Reference
applications to fill future
TDR/JCB(35)/12.13
vacancies
10:15-10:45 COFFEE BREAK
10:45-11:45 14. Review of TDR key achievements since Information
JCB(34) and outlook 2012-2013
Dr John Reeder will highlight TDR’s key achievements in
the last year and provide an outlook on expected results
in 2012-2013.
11:45-12:15 15. Summary of decisions and Review of decisions and
recommendations recommendations
The Rapporteur will present a summary of the
recommendations and decisions of JCB(35).
12:15-12:30 16. Closing session
Date and place of JCB(36) Decision on date and place of
JCB(36)
It is proposed that JCB(36) will be held in Geneva from
17-19 June 2013.
Any other business
Concluding remarks
Dr Sue Kinn and Dr Marie-Paule KienyTDR/JCB(35)/12.3
Page 18.
ANNEX 2
FINAL LIST OF PARTICIPANTS
MEMBERS
BELGIUM
Dr Ignace RONSE, Expert en santé publique des Programmes Multilatéraux et Européens, Ministère
de la Coopération au Développement, Bruxelles
BRAZIL
Not able to attend.
CHINA
Dr XIAO Ning, Deputy Director, National Institute of Parasitic Diseases (IPD), Shanghai
CONGO
Dr Paul Macaire OSSOU-NGUIET, Chef de Service Recherche et Equipement au CHU de
Brazzaville, Service de neurologie, CHU de Brazzaville, Brazzaville
CÔTE D'IVOIRE
Not able to attend.
CUBA
Dr Jorge PÉREZ, Director General, Institute of Tropical Medicine "Pedro Kourí" (IPK), La Habana
DJIBOUTI
Dr Houssein Youssouf DARAR, Head of Department, Infectious Diseases at Teacher Hospital
General Peltier, Focal point of Infectious Diseases Research (MOH), Djibouti
DRUGS FOR NEGLECTED DISEASES INITIATIVE
Dr Bernard PÉCOUL, Executive Director, Drugs for Neglected Diseases initiative (DNDi), Geneva,
Switzerland
ECUADOR
Dr Carlos Gregorio MONTALVO, National Secretary, Public Health Serveillance (Advisor),
Ministerio de Salud Pública, Quito
EGYPT
Dr Ayat Atef Mohamed HAGGAG, Undersecretary for Endemic Diseases, CairoReport of the 35th Session of the JCB
Page 19.
GERMANY AND LUXEMBOURG CONSTITUENCY
Dr Detlef BOECKING, Scientific Officer, PT-DLR, Project Management on behalf of the German
Federal Ministry of Education and Research (BMBF), Bonn, Germany
Professor Rolf KORTE, Senior Health Policy Advisor, Deutsche Gesellschaft für Internationale
Zusammenarbeit (GIZ) GmbH, Eschborn, Germany
Mme Anne WEBER, Agent de la Cooperation, Mission permanente du Grand-Duché de
Luxembourg auprès de l'Office des Nations Unies à Genève, Switzerland
INDIA AND THAILAND CONSTITUENCY
Dr Wanna HANSHAOWORAKUL, Director, Bureau of Knowledge Management, Department of
Disease Control, Ministry of Public Health, Royal Thai Government, Nonthaburi, Thailand
Dr Kanikaram SATYANARAYANA, Scientist G, Department of Health Research, Indian Council
of Medical Research, New Delhi, India
INDONESIA
Dr TRIHONO, Director General National Institute of Health Research & Development, Ministry of
Health, Jakarta Pusat
IRAN (ISLAMIC REPUBLIC OF)
Dr Payman HEMMATI, Expert in Influenza and IHR, Ministry of Health and Medical Education,
Tehran
IRAQ
Dr Ataallah M. Turky TURKY, Manager, Viral Hepatitis Department, Public Health Directorate,
Baghdad
JAPAN
Dr Haruka SAKAMOTO, Section Chief, Department of International Cooperation, Ministry of
Health, Labour and Welfare, Tokyo
LAO PEOPLE'S DEMOCRATIC REPUBLIC
Dr Kongsap AKKHAVONG, Acting Director General, National Institute of Public Health, Ministry
of Health, Vientiane Capital
MALAYSIA
Dr Shahnaz MURAD, Director, Institute for Medical Research, Ministry of Health, Kuala Lumpur
NEPAL
Dr Saroj Prasad RAJENDRA, Director, Management Division, Ministry of Health and Population,
Government of Nepal, Kathmandu
NIGERIA AND GHANA CONSTITUENCY
Professor Karniyus Shingu GAMANIEL, Director General, National Institute for Pharmaceutical
Research and Development (NIPRD), Garki - Abuja, NigeriaTDR/JCB(35)/12.3 Page 20. NORWAY AND SWITZERLAND CONSTITUENCY Mr Marc DE SANTIS, Programme Manager - Multilateral Affairs, East and Southern Africa, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation SDC, Bern, Switzerland Mrs Helga FOGSTAD, Head of Health, Department of Global Health, Education and Research, Norwegian Agency for Development Cooperation (NORAD), Oslo, Norway PERU Dr Cesar Augusto CABEZAS SÁNCHEZ, Medical Researcher, National Institute of Health, Lima PORTUGAL Not able to attend. REPUBLIC OF KOREA Dr KIM Jung-Yeon, Staff Scientist, Division of Malaria and Parasitic Diseases, Korea National Institute of Health, Korea Centers for Disease Control & Prevention, Chungbuk Dr LEE Won-Ja, Director, Division of Malaria & Parasitic Diseases, Korea National Institute of Health, Korea Centers for Disease Control & Prevention, Chungbuk SPAIN AND PANAMA CONSTITUENCY Dr Carlos SEGOVIA, Deputy Director for International Research Programmes and Institutional Relations, Instituto de Salud Carlos III, Madrid, Spain SWEDEN AND NETHERLANDS CONSTITUENCY Professor Maria Teresa BEJARANO, Senior Policy Specialist, Research, Swedish International Development Cooperation Agency - Sida, Stockholm, Sweden Ms Marja ESVELD, Senior Health Advisor, Social Development Department (DSO), The Hague, Netherlands Ms Henriëtte VAN GULIK, First Secretary, Permanent Mission of the Kingdom of the Netherlands to the United Nations Office and Other International Organizations at Geneva TAJIKISTAN Dr Sayfuddin KARIMOV, Director, National Center for Control of Tropical Diseases, Dushanbe Dr Rano RAHIMOVA, Chief Specialist, Department of Reform and International Relations, Ministry of Health, Dushanbe UNITED ARAB EMIRATES Not able to attend.
Report of the 35th Session of the JCB
Page 21.
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND AND UNITED STATES OF
AMERICA CONSTITUENCY
Dr Sue KINN, Team Leader Human Development, Research and Evidence Division, Department for
International Development (DFID), Glasgow, Great Britain
Mr Malcolm McNEIL, Senior Health Adviser, Human Development Team, Research and Evidence
Division, Department for International Development (DFID), London, Great Britain
Mr Martin SMITH, Deputy Programme Manager, DFID Research, Great Britain
ZAMBIA
Mr Evans MALIKANA, Chief Policy Analyst, Ministry of Health, Lusaka
Mr Samson LUNGO, First Secretary, Permanent Mission to the United Nations, Geneva
Dr Modest MULENGA, Director, Tropical Diseases Research Centre, Ndola
UNITED NATIONS CHILDREN'S FUND (UNICEF)
Ms Susie VILLENEUVE, Health Specialist, United Nations Children's Fund (UNICEF), Geneva,
Switzerland
UNITED NATIONS DEVELOPMENT PROGRAMME (UNDP)
Mr Jeffrey O'MALLEY, Director, HIV/AIDS Group, Bureau for Development Policy,
New York, NY, USA
WORLD BANK
Dr Armin FIDLER, Lead Health Policy Adviser, Human Development, World Bank,
Washington, DC, USA
Mrs Oksana PIDUFALA, Policy Officer, World Bank, Geneva, Switzerland
WORLD HEALTH ORGANIZATION
HEADQUARTERS, GENEVA, SWITZERLAND
Dr Bernadette ABELA-RIDDER, Scientist, Department of Food Safety and Zoonoses (FOS)
Foodborne Disease and Epidemiology
Dr Nicholas BANATVALA, Special Adviser to the Assistant Director-General, Noncommunicable
Diseases and Mental Health
Ms Gian Luca BURCI, Legal Counsel
Mr Nick JEFFREYS, Comptroller and Director, Department of Finance (FNM)
Dr Marie-Paul KIENY, Assistant Director-General, Innvovation, Information, Evidence and
Research
Dr Christian LIENHARDT, Senior Research Adviser, STB Policy, Strategy and InnovationsTDR/JCB(35)/12.3
Page 22.
Dr Simone MAGNINO, Scientist, Department of Food Safety and Zoonoses (FOS),
Foodborne and Zoonotic Diseases
Ms Anne MAZUR, Principal Legal Officer
Dr Hiroki NAKATANI, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected
Tropical Diseases
Dr Lorenzo SAVIOLI, Director, Neglected Tropical Diseases
SPECIAL PROGRAMME (TDR)
Ms Jamie GUTH, Communications Manager
Dr Beatrice HALPAAP, Programme and Portfolio Manager
Dr John REEDER, Director
Meinrad STUDER, Manager, External Relations and Governing Bodies
Fabio ZICKER, Coordinator, Research / Acting Coordinator, Stewardship and Empowerment
REGIONAL OFFICES
Regional Office for the Western Pacific
Dr John EHRENBERG, Director, Combating Communicable Diseases, Manila
SCIENTIFIC AND TECHNICAL ADVISORY COMMITTEE (STAC)1
Professor Mario Henry RODRIGUEZ-LOPEZ, Researcher at the Center for Research for Infectious
Diseases, National Institute of Public Health, Ministry of Health, Cuernavaca, Morelos, Mexico
TECHNICAL PRESENTERS
Dr Sodiomon Bienvenu SIRIMA, Scientific Team Leader, Ouagadougou, Burkina Faso
Professor David MOLYNEUX, Emeritus Professor and Senior Professorial Fellow, Liverpool
School of Tropical Medicine, Liverpool, United Kingdom
1
Dr M.H. Rodriguez-Lopez was also appointed to represent the Government of Mexico.Report of the 35th Session of the JCB
Page 23.
OBSERVERS
COHRED ‐ COUNCIL ON HEALTH RESEARCH FOR DEVELOPMENT (INCORPORATING THE
GLOBAL FORUM FOR HEALTH RESEARCH)
Dr Francisco SONGANE, Chair of the Steering Committee, Forum 2012, COHRED, Geneva,
Switzerland
FRANCE
Mme Geneviève CHEDEVILLE-MURRAY, Conseiller, Questions relatives à la santé, Mission
permanente de la France auprès des Nations Unies, Chambésy / Genève, Switzerland
INTERNATIONAL DEVELOPMENT RESEARCH CENTRE (IDRC)
Dr Dominique CHARRON, Program Leader, ECOHEALTH - Ecosystem Approaches to Human
Health, International Development Research Centre (IDRC), Ottawa (Ontario), Canada
MEXICO
Professor Mario Henry RODRIGUEZ-LOPEZ, Director, National Institute of Public Health,
Ministry of Health, Cuernavaca, Morelos
MYANMAR
Dr Htun Naing Oo, Director General, Department of Medical Research (Central Myanmar), Ministry
of Health, Nay Pyi Taw
SAUDI ARABIA
Mr Saud Faleh AL-NOFAIE, First Secretary, Permanent Mission of Saudi Arabia to the United
Nations in Geneva, 1292 Chambésy-Genève, Switzerland
Ms Sarah AL SHOURA, Permanent Mission of Saudi Arabia to the UN in Geneva
SIGHTSAVERS
Dr Elizabeth ELHASSAN, Regional Director, Sightsavers West Africa Regional Office, Dakar,
Sénegal
Dr Elena SCHMIDT, Head of Research, Sightsavers, Haywards Heath, United Kingdom
SRI LANKA
Dr Sunil DE ALWIS, Deputy Director General of Health Services, Education, Training and
Research, Ministry of Health, Colombo
WELLCOME TRUST
Dr Dermot MAHER, International Portfolio Manager, Wellcome Trust, London, United KingdomTDR/JCB(335)/12.3
Page 24.
A
ANNEX 3
MEM
MBERSHIIP OF TH
HE TDR JOINT
J COORDINNATING BOARD (JCB)
AS OF 1 JANUA
ARY 2013Report of the 35th Session of the JCB
Page 25.
ANNEX 4
MEMBERSHIP OF THE TDR STAC AS OF 1 JANUARY 2013
Term of Office
(until 31 December)
Professor Maged AL-SHERBINY, President, NAM S&T Centre and President, 2010-2013
Academy of Scientific Research and Technology (ASRT), Academy of Scientific
Research and Technology (ASRT), Cairo, Egypt
Professor Myriam AREVALO-HERRERA, Professor, School of Health, Department 2010-2013
of Clinical Laboratory, Universidad del Valle, Cali, Colombia
Dr Vicente Y. BELIZARIO, Jr., Vice-Chancellor for Research and Executive Director, 2008-2013
National Institutes of Health, University of the Philippines, Manila, Philippines
Dr Yves CHAMPEY, Chair, Strategic Committee for the Pole Development and its 2008-2013
Ecosystem (DevEco), Paris, France
Dr Carol A. DAHL, Executive Director, The Lemelson Foundation, Portland, USA 2008-2013
Professor Asma ELSONY, Director, The Epidemiological Laboratory, Khartoum, 2010-2013
Sudan
Professor Bruno GRYSEELS, Director, Institute of Tropical Medicine, Antwerpen, 2012-2013
Belgium
Dr Ikram GUIZANI, Head of Laboratory, Institut Pasteur de Tunis, 2012-2013
Ministère de la Santé Publique, Tunis-Belvedere, Tunisia
Dr Vishwa KATOCH, Secretary to the Government of India, Department of Health 2010-2013
Research & Director General, Indian Council of Medical Research, Ministry of Health
& Family Welfare, New Delhi, India
Dr Poloko KEBAABETSWE, Director, Health Service Research Unit, University of 2012-2013
Botswana, Gaborone, Botswana
Professor Christos (Kitsos) LOUIS, Chairman, Department of Biology, University of 2008-2013
Crete, Crete, Greece
Dr Florencia LUNA, Director, Bioethics Program of FLACSO, Latin American 2012-2013
University of Social Sciences, Buenos Aires, Argentina
Professor Lenore MANDERSON, Professor of Medical Anthropology and ARC 2012-2013
Federation Fellow and Director, Social Sciences and Health Research Unit, Caulfield
Campus, Monash University, Caulfield East, Australia
Professor Anne J. MILLS, Vice Director for Academic Affairs, London School of 2008-2013
Hygiene and Tropical Medicine, London, United Kingdom
Professor Mario-Henry RODRIGUEZ-LOPEZ, Researcher at the Center for Research 2009-2014
for Infectious Diseases, National Institute of Public Health, Morelos, Mexico
Dr Ananda Rajitha (Raj) WICKREMASINGHE, Dean of the Faculty of Medicine & 2012-2013
Professor of Public Health, Faculty of Medicine, University of Kelaniya, Ragama,
Sri LankaYou can also read
